Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Profit After Tax (2016 - 2025)

Lineage Cell Therapeutics' Profit After Tax history spans 16 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 131.03% year-over-year to $1.0 million; the TTM value through Dec 2025 reached -$63.4 million, down 240.78%, while the annual FY2025 figure was -$63.4 million, 240.52% down from the prior year.
  • Profit After Tax reached $1.0 million in Q4 2025 per LCTX's latest filing, up from -$29.8 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $1.0 million in Q4 2025 to a low of -$30.5 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$8.6 million, with a median of -$5.9 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: plummeted 1526.77% in 2021, then surged 131.03% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$29.0 million in 2021, then skyrocketed by 78.08% to -$6.4 million in 2022, then rose by 24.85% to -$4.8 million in 2023, then soared by 31.37% to -$3.3 million in 2024, then soared by 131.03% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Profit After Tax are $1.0 million (Q4 2025), -$29.8 million (Q3 2025), and -$30.5 million (Q2 2025).